CN113453677A - 用于治疗急性心房颤动的舒卡定施用 - Google Patents

用于治疗急性心房颤动的舒卡定施用 Download PDF

Info

Publication number
CN113453677A
CN113453677A CN201980092127.1A CN201980092127A CN113453677A CN 113453677 A CN113453677 A CN 113453677A CN 201980092127 A CN201980092127 A CN 201980092127A CN 113453677 A CN113453677 A CN 113453677A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
sulcatine
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980092127.1A
Other languages
English (en)
Chinese (zh)
Inventor
苏珊妮·J·罗马诺
加里·T·艾略特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huya Bioscience International LLC
Original Assignee
Huya Bioscience International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huya Bioscience International LLC filed Critical Huya Bioscience International LLC
Publication of CN113453677A publication Critical patent/CN113453677A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980092127.1A 2018-12-13 2019-12-12 用于治疗急性心房颤动的舒卡定施用 Pending CN113453677A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779056P 2018-12-13 2018-12-13
US62/779,056 2018-12-13
US201962858324P 2019-06-06 2019-06-06
US62/858,324 2019-06-06
PCT/US2019/066003 WO2020123824A1 (en) 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
CN113453677A true CN113453677A (zh) 2021-09-28

Family

ID=69165588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092127.1A Pending CN113453677A (zh) 2018-12-13 2019-12-12 用于治疗急性心房颤动的舒卡定施用

Country Status (11)

Country Link
US (4) US11364223B2 (https=)
EP (1) EP3893870A1 (https=)
JP (1) JP2022514537A (https=)
KR (1) KR20210135990A (https=)
CN (1) CN113453677A (https=)
AU (1) AU2019397511B2 (https=)
CA (1) CA3123078A1 (https=)
IL (1) IL283931A (https=)
MX (1) MX2021006933A (https=)
WO (1) WO2020123824A1 (https=)
ZA (1) ZA202104166B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984004A (zh) * 2022-05-25 2022-09-02 扬州中宝药业股份有限公司 硫酸舒欣啶在制备抗脓毒症药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120245214A1 (en) * 2009-11-17 2012-09-27 Elliott Gary T Slow infusion of sulcardine and its salts
US20120309810A1 (en) * 2009-11-17 2012-12-06 HUYA Bioscience International Treatment of atrial fibrillation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
JP5308333B2 (ja) 2006-06-30 2013-10-09 シグマ−タウ レア ディジージズ エスィアー Ｌ−アスパラギナーゼｉｉを産生する組換え宿主
EP2468869B1 (en) 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
KR102092225B1 (ko) 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
CN107532190B (zh) 2014-12-01 2021-07-09 菲尼克斯公司 用于肽生产的融合伴侣
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120245214A1 (en) * 2009-11-17 2012-09-27 Elliott Gary T Slow infusion of sulcardine and its salts
US20120309810A1 (en) * 2009-11-17 2012-12-06 HUYA Bioscience International Treatment of atrial fibrillation
CN104324024A (zh) * 2009-11-17 2015-02-04 沪亚生物国际有限责任公司 心房纤颤的治疗

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984004A (zh) * 2022-05-25 2022-09-02 扬州中宝药业股份有限公司 硫酸舒欣啶在制备抗脓毒症药物中的应用
CN114984004B (zh) * 2022-05-25 2023-09-12 扬州中宝药业股份有限公司 硫酸舒欣啶在制备抗脓毒症药物中的应用

Also Published As

Publication number Publication date
IL283931A (en) 2021-07-29
AU2019397511A1 (en) 2021-07-22
MX2021006933A (es) 2021-09-30
US20250302805A1 (en) 2025-10-02
US20240115548A1 (en) 2024-04-11
US12357611B2 (en) 2025-07-15
WO2020123824A1 (en) 2020-06-18
AU2019397511B2 (en) 2025-08-21
US20200188357A1 (en) 2020-06-18
JP2022514537A (ja) 2022-02-14
CA3123078A1 (en) 2020-06-18
US11883380B2 (en) 2024-01-30
EP3893870A1 (en) 2021-10-20
US20220280480A1 (en) 2022-09-08
US11364223B2 (en) 2022-06-21
ZA202104166B (en) 2023-11-29
KR20210135990A (ko) 2021-11-16

Similar Documents

Publication Publication Date Title
US8569325B2 (en) Method of treatment with coadministration of aspirin and prasugrel
KR101125462B1 (ko) 모다피닐의 제약 제제
CN113453677A (zh) 用于治疗急性心房颤动的舒卡定施用
US7834056B2 (en) Pharmaceutical composition for gout
CN102869357A (zh) 舒欣啶及其盐的缓慢滴注
SK7292002A3 (en) Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4
TW201813645A (zh) 含鹽皮質激素受體拮抗劑的藥物組合物及其用途
AU666992B2 (en) Pharmaceutical composition for preventing or treating arteriosclerosis
US12465587B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
US3932652A (en) Antidepressant compositions
JPH03505447A (ja) アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物
CN114401724B (zh) 一种降糖药物组合物
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
US20060009475A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
US4716177A (en) Tolrestat for inhibition of weight gain
HK1056118B (en) Medicinal compositions containing aspirin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061591

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Huya biological International Co.,Ltd.

Address before: California, USA

Applicant before: HUYA BIOSCIENCE INTERNATIONAL LLC